Research programme: Alzheimer's disease therapies - Icogenex
Alternative Names: EPα; EPβLatest Information Update: 04 Nov 2017
At a glance
- Originator Icogenex Corporation
- Class Peptides; Small molecules
- Mechanism of Action Amyloid beta-protein precursor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 10 Oct 2012 Early research in Alzheimer's disease in USA (unspecified route)
- 23 Feb 2004 Icogen Corporation is now called Icogenex Corporation